Skip to Content
Upcoming Webinar

An Innovative Therapy for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Date: June 3, 2025 | 2:00 PM

AVMAPKI FAKZYNJA CO-PACK
An Innovative Therapy for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

KRAS-mutated low-grade serous ovarian cancer (LGSOC) involves distinct clinical considerations and limited established treatment options. As new therapies emerge, understanding their mechanisms, supporting evidence, and clinical application is essential for informed care.

Featured Speaker:
Sarah Hayward, PharmD, BCOP
Stephenson Cancer Center at OU Health

What’s We’ll Discuss:

  • The clinical profile and treatment landscape of KRAS-mutated LGSOC
  • Dual MEK and FAK inhibition: rationale and mechanism of action
  • Key efficacy and safety data from the RAMP-201 trial
  • Practical guidance on dosing, monitoring, and potential drug interactions
  • Patient selection and real-world decision-making

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.